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ABSTRACT 
Objective: Sporadic inclusion body myositis (sIBM) pathogenesis is unknown; however, rimmed vacuoles (RVs) are a 
constant feature. We propose to identify proteins that accumulate within RVs. 
Methods: RVs and intact myofibers were laser microdissected from skeletal muscle of 18 sIBM patients and analyzed 
by a sensitive mass spectrometry approach using label-free spectral count-based relative protein quantification. Whole 
exome sequencing was performed on 62 sIBM patients. Immunofluorescence was performed on patient and mouse 
skeletal muscle. 
Results: 213 proteins were enriched by >1.5X in RVs compared to controls and included proteins previously reported to 
accumulate in sIBM tissue or when mutated cause myopathies with RVs. Proteins associated with protein folding and 
autophagy were the largest group represented. One autophagic adaptor protein not previously identified in sIBM was 
FYCO1. Rare missense coding FYCO1 variants were present in 11.3% of sIBM patients compared with 2.6% of controls 
(p=0.003). FYCO1 co-localized at RVs with autophagic proteins such as MAP1LC3 and SQSTM1 in sIBM and other 
RV myopathies. One FYCO1 variant protein had reduced co-localization with MAP1LC3 when expressed in mouse 
muscle. 
Interpretation: This study used an unbiased proteomic approach to identify RV proteins in sIBM that included a novel 
protein involved in sIBM pathogenesis. FYCO1 accumulates at RVs and rare missense variants in FYCO1 are 
overrepresented in sIBM patients. These FYCO1 variants may impair autophagic function leading to RV formation in 
sIBM patient muscle. FYCO1 functionally connects autophagic and endocytic pathways supporting the hypothesis that 
impaired endolysosmal degradation underlies the pathogenesis of sIBM. 
 
Keywords 
Sporadic inclusion body myositis; rimmed vacuoles; FYCO1 
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INTRODUCTION  
Sporadic inclusion body myositis (sIBM) is the most common idiopathic inflammatory myopathy (IIM) in people over 
50 years of age. It causes progressive muscle weakness, especially of finger flexion and knee extension. It is uncertain 
whether sIBM is a primarily inflammatory or a degenerative myopathy. In contrast to other IIM, conventional 
immunosuppressants and immunomodulatory regimens have not been found to alter disease progression.
1,2
 Typical 
myopathological features are inflammatory and degenerative changes, accompanied by rimmed vacuoles (RV) and 
protein aggregates.
2–6
 The current manuscript intentionally focuses on these “degenerative features” in order to gain 
insight into one aspect of sIBM pathogenesis. 
RVs are characteristic for the disease and are a useful diagnostic pathological feature; however their genesis remains 
enigmatic.
2,5
 They are reported to contain both sarcoplasmic and myonuclear proteins. It has been suggested that the 
origin of a RV is due to myonuclear breakdown since both nuclear and nuclear envelope proteins are present in or 
adjacent to the RV.
7
 Others have identified autophagic, lysosomal and endosomal protein markers within and 
surrounding RVs.
4,8,9
 This has led to the hypothesis that impairment of autophagic degradation underlies sIBM 
pathogenesis. Finally, many proteins present in protein aggregate diseases such as Alzheimer’s Disease, amyotrophic 
lateral sclerosis and protein aggregate myopathies are consistently found accumulated in sIBM muscle suggesting that 
sIBM is a degenerative proteinopathy akin to neurodegenerative disorders. RVs are typical of sIBM pathology, but they 
are not specific and are also found in a number of inherited myopathies including myofibrillar myopathies, hereditary 
distal myopathies and rare inherited inclusion body myopathies due to mutations in GNE and VCP.
10,11
 In these 
disorders, the disease associated mutant protein accumulates within degenerating myofibers often within or adjacent to 
RVs. 
Previously we established a combined laser microdissection and label-free proteomic approach to analyze cytoplasmic 
protein aggregates in myofibrillar myopathies.
11–13
 Using this technique, we identified distinct protein signatures in the 
muscle of myofibrillar myopathy patients. In the present study, we utilize the same proteomic approach to identify the 
protein composition of RVs in sIBM. We hypothesize that RV enriched proteins are pathogenic mediators of disease and 
will inform both genetic association and sIBM biomarker development.  
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MATERIALS AND METHODS 
Patients and muscle biopsies 
Studies were performed on muscle samples from 18 patients with sIBM (6 women, 12 men, mean age 66.7±10.7 years, 
range 49-93 years) according to local ethics committee regulations (reg. number 3882-10). The diagnosis of sIBM was 
based on the recently published 2011 European Neuromuscular Centre international workshop criteria.
5
 After surgical 
procedure, skeletal muscle biopsies were divided into 0.5 cm
3 
pieces, embedded into Tissue Freezing Medium® (Leica 
Microsystems, Wetzlar, Germany) and flash frozen in liquid nitrogen. 
DNA was collected on 62 patients with a diagnosis of sIBM.
5
 40/62 patients had been previously reported and targeted 
sequencing for hereditary causes of muscle disease had been performed.
14
 An additional 12 patients were identified in 
the Washington University Neuromuscular Clinic and 10 patients from Johns Hopkins University. All participants gave 
written informed consent, and study procedures were approved by the Human Studies Committee at Washington 
University. 
 
Proteomic analysis 
Laser microdissection and sample processing  
A combined laser microdissection and label free mass spectrometry approach was applied as described with 
modifications.
13,15
 Ten µm thick frozen skeletal muscle sections were placed on polyethylene terephthalate (PET) 
membranes (Leica Microsystems, Wetzlar, Germany) and stained with hematoxylin and eosin (H&E). These sections 
were used to collect (from each patient) a total area of 250,000 µm
2
 of RV and surrounding sarcoplasm (hereinafter 
referred as RV sample) and the same area of vacuole-free sarcoplasm in normally looking muscle fibers (control sample) 
by laser microdissection (LMD 6500, Leica Microsystems, Wetzlar, Germany) into tubes containing 40 µl of 98-100% 
formic acid. After incubation for 30 min and sonification (35 kHz) for 5 min (RK31, BANDELIN electronic, Berlin, 
Germany), samples were centrifuged at 12,000 g for 10 min at 4°C and frozen at -80°C. The in-solution digestion and 
sample processing was performed as described.
13,15
 
 
Nano high performance liquid chromatography (HPLC) and mass spectrometry (MS)  
The HPLC-MS analysis was performed on a nano-HPLC system UltiMate 3000 RSLCnano (Dionex, Idstein, Germany) 
interfaced to a quadrupole orbitrap mass spectrometer (Q Exactive; Thermo Fischer Scientific, Germany). HPLC-
analysis was performed as described before.
13
 After nano-HPLC separation peptides were ionized in a nano electrospray 
ionization source (ESI) and analyzed in data dependent scan mode in the Q Exactive mass spectrometer. Full MS spectra 
were scanned between 350 and 1,400 m/z with a resolution of 70,000 at 200 m/z (AGC target 3e6, 80ms maximum 
injection time). The capillary temperature was set at 250°C and the spray voltage at 1600 V (+). Lock mass 
polydimethylcyclosiloxane (m/z 445.120) was used for internal recalibration. The m/z values initiating MS/MS were set 
on a dynamic exclusion list for 30s and the 10 most intensive ions (charge +2, +3, +4) with intensity higher than 1.7e3 
were selected for fragmentation. Tandem MS fragments were generated by higher energy collision induced dissociation 
and the fragmentation was performed with 27% normalized collision energy. The first MS/MS mass was fixed at 130.0 
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m/z and isolation window 2.2 m/z. The fragments were injected into the orbitrap analyzer with 35,000 resolution at 2,000 
m/z (AGC 1e6, maximum injection time 120 ms). 
 
Database search and relative protein quantification 
After ESI-MS/MS analysis mass spectrometric data were searched against a human protein database containing the 
entire UniProt/Swiss-Prot (release 2014/05/28, 20265 curated entries) using Mascot (version 2.5)
16
 and label-free relative 
protein quantification based on spectral counting was performed as described
13
 using PIA.
17
 To identify proteins that 
were overrepresented in RV within muscle fibers in sIBM, the ratios between the averaged proportions of proteins in RV 
and control samples were calculated and a two-tailed unpaired t-test (equal variances assumed) was performed for each 
protein. A protein was accepted as significantly overrepresented if the RV/control ratio was >1.5 and the p-value <0.05. 
 
Validation of proteomic findings by immunofluorescence studies  
Immunofluorescence studies were performed on muscle samples from five sIBM patients to validate the proteomic 
findings as described.
6,13
 Serial frozen skeletal muscle sections were incubated overnight at 4°C with primary antibodies 
against 21 proteins (Supplementary Table 1), followed by washing steps and incubation with isotope specific secondary 
antibodies conjugated with Alexa Fluor 488 (Dianova, Hamburg, Germany; dilution 1:1,000) or Texas Red (Dianova, 
Hamburg, Germany; dilution 1:400). Nuclei were visualized by 4´,6-diamidino-2-phenylindole (DAPI) staining (Roche 
Diagnostics, Indianapolis, IN, USA; dilution 1:10,000). 
  
Whole exome sequencing (WES) 
Indexed genomic DNA libraries were prepared from genomic DNA using TruSeq DNA Preparation Kit (Illumina, San 
Diego, CA, USA) and exome capture using TruSeq Exome Enrichment Kit (Illumina), according to the manufacturer’s 
protocol. Sequencing was performed with 100 bp paired-end reads on a HiSeq2000 (Illumina). Reads were aligned to the 
human reference genome with NovoAlign (Novocraft Technologies, Selangor, Malaysia) or Burrows-Wheeler Aligner.
18
 
Variants were called with SAMtools
19
 and annotated with SeattleSeq. Coverage across genomic intervals was calculated 
using BEDTools.
20
 Genomic coordinates for regions targeted by the whole-exome capture kit were provided by Illumina. 
Whole exome sequences from 62 sIBM patients were filtered for variants that: 1) had a minor allele frequency of ≤0.001 
in the ExAC Database; 2) generated a loss of function variant or a nonsynonymous change; and 3) fulfilled a strict 
sequence quality as defined by Genesis 2.0 software. 
 
Mouse expression studies 
GFP-FYCO-WT and mCherry-LC3 expressing plasmid constructs were obtained from Dr. Terje Johansen. The LIRmut 
(F1280A/I1283A), T1270A and P1302L point mutations were generated via site directed mutagenesis. For 
electroporation, mice were anesthetized using inhaled isoflurane. The skin overlying the TA muscle was shaved, and the 
animals were co-injected with 30 µg endotoxin-free expression plasmid (diluted in sterile phosphate-buffered saline 
(PBS) to a volume of 50 µl by using a 0.5 ml syringe fitted with a 29-gauge needle. Two-needle array electrodes 
(450121) (Harvard Apparatus, Holliston, MA, USA) were inserted into the muscle immediately after DNA delivery for 
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electroporation. The distance between the electrodes was 5 mm, and the array was inserted longitudinally relative to the 
muscle fibers. In vivo electroporation parameters were the following: voltage, 75 V; pulse length, 50 ms; number of 
pulses, six pulses; pulse interval, 200 ms; desired field strength, 200 V/cm, given by a BTX ECM830 Electro Square 
Porator. Animals were allowed to recover for 7 days prior to muscle isolation which was frozen in liquid nitrogen cooled 
isopentane and processed into 10uM section. Slides were examined using a fluorescent microscope (80i upright; Nikon) 
and charge-coupled device camera (EZ monochrome; Roper Industries) with deconvolution software analysis (NIS 
Elements; Nikon). Image processing and analysis were performed with NIS Elements 4.0 software and Photoshop CS3 
(Adobe). All images were performed on fixed tissue at room temperature using Prolong Gold mounting solution 
(Invitrogen). Objectives used for immunofluorescence were Apochromat 20× and 40×. For colocalization analysis, 40 
random fibers from three experiments were selected. The Pearson’s colocalization coefficient was determined for each 
fiber using NIS Elements 4.0 software. All images were taken at the same gain and exposure intensity. 
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RESULTS 
Proteomic analysis 
In total 3873 different proteins were identified by mass spectrometric analysis including 213 proteins that showed a 
statistically significant over-representation in RV samples compared to controls (see Supplementary Table 1). The 
proteins were assigned to subgroups based on their main physiological cell function. The proportion of each subgroup 
related to the sum of spectral counts is shown in Fig. 1. Intermediate filaments were the most abundant overrepresented 
proteins, followed by proteins of the extracellular matrix and by proteins involved in cell stress response, protein quality 
control and protein degradation (Fig. 1). The latter group contains 29 different proteins including three proteins that were 
detected in >50% of RV samples but in none of the control samples: transaldolase (an enzyme of the pentose-phosphate 
pathway), p62 (SQSTM1), and FYVE and coiled-coil domain-containing protein 1 (FYCO1).  
 
Genetic Analysis  
We reasoned that the proteins overrepresented in RVs may facilitate the identification of potential genetic risk alleles for 
sIBM. To test this, we identified rare missense or loss of function (LoF) variants in genes that encoded proteins that were 
present in ≥50% of RV samples (131 genes, see Supplementary Table 1) using WES of 62 patients with sIBM. This 
analysis identified 100 variants from 52 genes. 17 genes had variants in two or more sIBM patients (see Table 1). To see 
if the burden of variants within a single gene was increased in other diseased control populations, or if this enrichment 
was specific to sIBM, we determined the number of rare missense of LoF variants within these 17 genes in sporadic 
amyotrophic lateral sclerosis (ALS) patients from an existing WES dataset. Using this data we found that variants in only 
one gene were statistically enriched in sIBM patients with a p value of ≥0.01. Specifically, 7/62 (11.3%) of sIBM 
patients carried a rare missense or LoF FYCO1 variant as compared with 18/680 (2.6%) of ALS patients (p 
value=0.0029) (Table 1). Similarly, the burden of FYCO1 variants in sIBM was significantly enriched (p value=0.011) 
when compared with ethnically matched patient genomes within the 1000 genomes database with 17/503 carrying a rare 
missense or LoF variant in FYCO1. sIBM associated FYCO1 rare variants were present throughout the protein although 
two variants were adjacent to or within the LC3 interacting region (LIR) domain (Supplementary Table 2, Fig. 2).
21
 
 
Validation of proteomic data by double immunofluorescence staining 
Our proteomic and genetic data suggested that FYCO1 was an intriguing candidate protein to explore further. FYCO1 
binds to LC3 and other vesicular cargo facilitating autophagic degradation.
22
 We found that RVs displayed 
immunoreactivity for FYCO1, the autophagic adaptor p62 and the autophagosome protein MAP1LC3 in sIBM patients, 
with a slightly stronger immunoreactivity for FYCO1 (Fig. 3, copy using magenta-green coloring for readers who are 
red-green color blind in Supplementary Fig. 1). Therefore, we used FYCO1 as a marker for RV in double 
immunofluorescence analyses to evaluate 18 additional proteins from different subgroups identified as enriched in RV 
samples by our proteomic analyses (Fig. 4 and 5, magenta-green copies in Supplementary Fig. 2 and 3). The 
immunoreactivity for these proteins was increased inside RVs or very closely around them, matching the area that has 
been collected by laser microdissection and thus confirming our mass spectrometric data. 
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FYCO1 localization in other vacuolar myopathies and idiopathic inflammatory myopathies 
To assess the specificity of FYCO1 for RV, we performed immunofluorescence staining on skeletal muscle sections 
from patients with hereditary inclusion body myopathy caused by GNE mutations, filaminopathy associated with a 
myofibrillar myopathy phenotype, glycogen storage disorder type II (Pompe’s disease) and normal control muscle tissue. 
The sarcolemma was marked with an antibody to spectrin (Fig. 6, magenta-green copy in Supplementary Fig. 4). FYCO1 
was associated with RVs in hereditary inclusion body myopathy, glycogen storage disorder type II and filaminopathy. In 
filaminopathy, immunoreactivity for FYCO1 was increased in RV and in sarcoplasmic aggregates (Fig. 6).  In 
dermatomyositis, some perifascicular muscle fibers showed an increased immunoreactivity for FYCO1 but “punched-
out” areas of myofibrillar loss were not rimmed or markedly filled with FYCO1. In polymositis and in sIBM with a 
morphological phenotype of polymyositis, muscle fibers surrounded by inflammatory cells displayed a diffuse/punctate 
immunoreactivity for FYCO1. In addition, some fibers showed FYCO1 accumulations in subsarcolemmal areas similar 
to that found in RV areas in sIBM. These areas were basophilic in H&E staining (Fig.6).  FYCO1 immunostaining and 
its co-localization to autophagic proteins (LC3 and p62) at RVs were similar in three sIBM patients carrying FYCO1 
variants as compared with co-localization in sIBM patients not carrying a FYCO1 variant (data not shown). 
  
FYCO1 variant localization in mouse muscle 
FYCO1 is reported to facilitate the transport of autophagosomes along microtubules via its association with LC3.
22
 Two 
identified missense variants, FYCO1-T1270A and FYCO1-P1302L, are adjacent to or within the LC3 interacting region 
domain (LIR) suggesting they may alter LC3 interaction (Supplementary Table 2, Fig. 2). We co-electroporated a 
plasmid expressing mCherry tagged LC3 with a plasmid expressing green fluorescent protein tagged FYCO1-WT in 
mouse tibialis anterior muscle. After seven days muscle was sectioned and visualized via fluorescent microscopy. GFP-
FYCO1-WT was present as small puncta throughout the sarcoplasm that co-localized with mCherry-LC3 (Figure 7A-C). 
Expression of FYCO1 with two point mutations within the LIR domain that abolish LC3 interaction, GFP-FYCO1-
LIRmut, demonstrated a similar pattern of GFP-FYCO1 puncta but diffuse mCherry-LC3 with reduced co-localization 
(Figure 7D-F). This pattern of reduced FYCO1/LC3 colocalization was also seen with the sIBM variant, GFP-FYCO1-
P1302L (Figure 7G-I) but not with GFP-FYCO1-T1270A (Figure 7J-L). The degree of GFP-FYCO1/mCherry-LC3 co-
localization was quantified from co-expressing fibers/condition from three independent experiments and was 
significantly reduced in GFP-FYCO1-P1302L expressing fibers compared to GFP-FYCO1-WT controls (Figure 7M). 
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DISCUSSION 
In this study, we applied for the first time a highly sensitive proteomic approach to analyze the composition of a 
characteristic histopathological feature in sIBM. We used laser microdissection to collect RV and intraindividual control 
samples from muscle sections of sIBM patients. Mass spectrometric analysis and relative protein quantification allowed 
us to identify 213 proteins accumulated in RV samples compared to controls. Forty of these overrepresented proteins 
have already been described in sIBM (see Supplementary Table 1). Thus, the results of these previous studies validate 
our method and findings. Many of the proteins overlap with those identified in other protein aggregate myopathies
11–13
 
making most of the identified proteins not specific for sIBM but rather highlights converging pathogenic mechanisms 
with other muscle diseases. We also identified 173 proteins which have not been described in sIBM previously, which 
provides a basis for future studies to further investigate disease mechanisms. Our approach of label-free proteomic 
analysis combined with next generation sequencing has enabled us to identify a possible new genetic risk factor for 
sIBM. 
 
We categorized the overrepresented RV proteins by their main cellular function and performed extensive 
immunofluorescence studies to further evaluate selected members of the different protein subgroups. These analyses 
confirmed and validated our proteomic data. We found that intermediate filaments were the most abundant 
overrepresented components in RV samples and immunolocalization analysis proved that distinct intermediate filaments 
accumulate in RV areas. Very few studies have investigated intermediate filaments in sIBM.
23-26
 Olivé et. al. showed an 
accumulation of desmin in muscle fibers from patients with sIBM.
23
 One proteomic study revealed an increase of 
vimentin in whole muscle biopsies
24
 and two studies described nestin and vimentin in regenerating muscle fibers.
25,26
 
The surprising abundance of intermediate filaments in RVs is new but their exact role in RV genesis needs further 
investigation. Intermediate filaments are engaged in the formation and organization of aggregated and misfolded 
proteins.
27
 Intracellular protein aggregates are transported along microtubules to form larger aggresomes finally removed 
by autophagic degradation.
27,28
 The intermediate filament protein vimentin forms a cage-like structure around 
aggresomes and is also responsible for lysosome organization and transport.
28,29
 The abundance of intermediate filaments 
around RVs may suggest that they support autophagic degradation in muscle fibers of sIBM patients. It is notable that 
mutations in the intermediate filament desmin causes a myopathy with rimmed vacuoles.
10
 
 
The largest group of proteins identified as overrepresented in RV areas is those associated with protein folding and 
degradation. Protein homeostasis or “proteostasis” likely plays an important role in sIBM pathogenesis and is thus a 
tractable therapeutic target.
30
 Our study reveals that several new chaperone components may be relevant and refine 
therapeutic strategies. Small heat shock proteins and other molecular chaperones are of particular interest since they 
facilitate proper protein folding and degradation of misfolded and aggregated proteins. αB-crystallin, 78 kDa glucose-
regulated protein and calreticulin have already been described in sIBM.
31-34
 A new finding is the enrichment of 
components of the TCP-1 ring complex (TRiC, also called CCT for chaperonin containing TCP1). Interestingly, an over-
representation of these proteins was not detected in other protein aggregate myopathies (
11–13
 and unpublished data) and 
it may therefore be a specific feature of sIBM that needs further investigations. TRiC is a central chaperonin complex 
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that interacts with approximately 5-10% of cytosolic proteins
35
 and seems to be important for the prevention of protein 
aggregation and toxicity.
35-37
 Moreover, TRiC is a regulator of the heat shock transcription factor 1 (HSF1) in muscle 
fibers.
38,39
 It directly interacts with HSF1 and represses HSF1 activity.
38
 It would be interesting to know if TRiC affects 
the efficacy of arimoclomol – a pharmacological agent that prolongs the activation of HSF1. Arimoclomol is currently in 
clinical trials for the treatment of sIBM.
30
 
 
Of the 213 proteins found enriched at RVs, disease mutations in twenty-two of these proteins lead to muscle related 
phenotypes including nine proteins associated with myopathies containing prominent RV pathology. This may not be 
surprising since several studies have demonstrated the utility of proteomics for the identification of accumulated proteins 
that are ultimately found to be the genetic cause of the disease.
40,41
 These previous reports led us to evaluate the burden 
of rare coding variants in RV accumulated proteins in sIBM patients. Current genetic studies in sIBM are limited. Some 
studies have performed targeted genetic mutation analysis in small cohorts of sIBM patients
14
 whereas other studies have 
focused on modifier genes within populations of sIBM patients such as HLA subtypes as means to correlate MHC gene 
alleles with sIBM severity and prognosis.
42
 However, no studies have identified a clear risk allele for sIBM. One 
challenge to sIBM genetics relates to the rarity of the disease and its late onset which usually precludes obtaining 
parental DNA. Therefore obtaining patient samples with the statistical power necessary to perform genome wide 
associations is difficult. To circumvent this, the current study uses proteomic candidates to explore potential genetic risk 
factors. Indeed, rare variants in FYCO1 were found in 11.3% of sIBM patients as compared with 2.6% of disease 
controls and 3.4% of population controls. We suggest that rare variants in FYCO1 are associated with risk of developing 
sIBM. This would be similar to other recently identified genetic risk variants such as TREM2 and TBK1 in sporadic 
amyotrophic lateral sclerosis where there is an overrepresentation of rare missense and LoF variants in cases as 
compared to matched controls.
43,44
 It is important to note several limitations of our genetic study. In particular, the small 
sample size of 62 sIBM patients. Future studies will be necessary to explore whether FYCO1 remains a risk factor for 
sIBM in larger cohorts. It will also be interesting to see whether FYCO1 variants explain the pathogenesis or modify the 
phenotype of other myopathies with RVs. 
 
FYCO1 belongs to an emerging group of autophagic adaptor proteins.
45
 These adaptors facilitate autophagic cargo 
loading, autophagosome to lysosome maturation or in the case of FYCO1, autophagosome/endosome trafficking.
45
 
FYCO1 binds to LC3 and Rab7 on the surface of autophagosomes and endosomes, respectively, links them to 
microtubules via kinesin, and enables transport of autophagosomes along microtubules to acidic lysosomes.
22,46
 
Depletion of FYCO1 or point mutations within its LC3 interacting region (LIR) domain lead to the accumulation of 
autophagosomes and autophagic cargo that have failed to mature to autolysosomes and be degraded.
21
 We identified two 
rare FYCO1 variants (T1270A and P1302L) that resided in or adjacent to the LIR domain. In mouse skeletal muscle, 
FYCO1-WT co-localizes with LC3 puncta. In contrast, deletion of the LIR domain or expression of the FYCO1-P1302L 
variant failed to recruit and localize to LC3 puncta suggesting that this sIBM associated FYCO1 missense variants may 
disrupt its function. Missense variants in FYCO1 have been previously identified in rare patients with congenital 
cataracts.
47
 Interestingly, expression of these variants did not disrupt FYCO1’s association with LC3 suggesting that loss 
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of LC3 interaction is not the only mechanism by which FYCO1 mutations can disrupt its function. Indeed, the role of 
FYCO1 in normal skeletal muscle is currently unknown.  The fact that FYCO1 localizes throughout the myofiber in 
control mouse muscle and in myopathies lacking RVs such as dermatomyositis and polymyositis supports a role for 
FYCO1 in processes unrelated to its pathologic accumulation at RVs. 
 
Our study identified an overrepresentation of rare missense coding variants in FYCO1 in sIBM patients and suggests that 
a failure in autophagosome/endosome trafficking may underlie sIBM pathogenesis. The role of impaired vesicular 
trafficking along microtubules in vacuolar myopathies is further supported by patients and animals treated with 
colchicine, a microtubule destabilizing agent. Mice chronically treated with colchicine develop an autophagic vacuolar 
myopathy with the accumulation of LC3, p62 and late endosomal markers such as Lamp2.
48
 This also occurs in patients 
receiving toxic doses of colchicine.
48
 Similarly, RVs in sIBM seem to agglomerate, which hint at ineffective or 
inadequate transport mechanisms along the cytoskeleton. It is intriguing that dominantly inherited mutations in two other 
proteins (VCP and p62/SQSTM1) also responsible for autophagosome maturation/degradation lead to RV myopathies.
49–
52
 Notably, VCP and p62 were both identified as RV enriched proteins in the current study. Moreover, rare missense 
pathogenic variants in both VCP and SQSTM1 have been found in patients with sIBM.
14,53
  
The pathogenesis of sIBM is uncertain and likely due multiple contributing factors. Specifically, a combination of 
environmental, genetic and aged risk factors needs to be present for disease manifestation. Although our study has 
identified a potential risk allele in a gene associated with autophagic degradation, this does not preclude the possibility 
that a primary immune process instigates sIBM pathogenesis. Indeed, a FYCO1 missense variant is not sufficient for 
disease pathogenesis since all of our sIBM patients lacked a family history of sIBM or weakness. However, it is 
intriguing that several genes associated with autophagosome-lysosome processing are emerging as risk alleles in 
sIBM.
14,53
 Future therapies aimed at improving autophagic function may be beneficial in sIBM patients, especially when 
used in conjunction with other therapies addressing immune dysfunction. 
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FIGURE LEGENDS 
Figure 1: Functional classification of proteins identified as overrepresented in RV samples by proteomic analysis. 
Bar chart showing the sum of the mean proportion of proteins assigned to a subgroup is given for RV and control 
samples in per mill of total spectral counts. The number of detected proteins is given in brackets behind the subgroup 
name. Black bars show the proportion in RV samples and grey bars the proportion in control samples. Details of proteins 
assigned to the different subgroups are provided in Supplementary Table 1. ER: endoplasmic reticulum.  
 
Figure 2: Scheme of FYCO1. Black arrows denote sites of missense variants identified in patients with sIBM. Red 
arrows denote mutations previously identified in patients with congenital cataracts. Domains include RUN (GTPase 
interacting motif); Coiled Coil (dimerization motif); FYVE (phospholipid binding region); LIR (LC3 interacting region); 
and GOLD (golgi dynamics domain). 
 
Figure 3: Co-localization of FYCO1, p62 and LC3 in RVs of sIBM patients. Serial skeletal muscle sections from two 
sIBM patients (patient 1: A-H, patient 2: I-P) and from a healthy control (Q-T) were stained with H&E and double-
immunostained with primary antibodies directed against FYCO1 (green) and p62 or LC3 (red). Nuclei are stained with 
DAPI (blue). For each sIBM patient two different RV containing areas of the muscle samples are displayed. All RVs 
show a strong immunoreactivity for FYCO1, p62 and LC3. The co-localization of FYCO1 with p62 LC3 is indicated by 
yellow in the merged images. Scale bar = 50 µm. 
 
Figure 4: Validation of proteomic findings by immunolocalization studies I. Serial sections from two sIBM patients 
were stained with H&E and double-immunostained with antibodies recognizing desmin, nestin, syncoilin, fibrillin-1, 
nexilin, N-RAP, XIRP-2, leiomodin-2, clusterin, rab35, synaptogyrin, and alphaB-crystallin. All proteins showed an 
accumulation in RV samples (red) and FYCO1 (green) as a positive control to localize RVs. Nuclei are stained with 
DAPI (blue). Increased immunoreactivity was observed with all proteins as indicated by yellow in the merged image. 
Scale bar = 50 µm. 
 
Figure 5: Validation of proteomic findings by immunolocalization studies II. Serial sections from two sIBM patients 
were stained with H&E and double-immunostained with antibodies recognizing calreticulin, GRP78/BiP, AHNAK, 
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dysferlin, δ-sarcoglycan and dystrophin All proteins showed an accumulation in RV samples (red) and FYCO1 (green) 
as a positive control to localize RVs. Nuclei are stained with DAPI (blue). Increased immunoreactivity was observed 
with all proteins as indicated by yellow in the merged image. Scale bar = 50 µm. 
 
Figure 6: Localization of FYCO1 in hereditary myopathies with rimmed vacuoles and in idiopathic inflammatory 
myopathies. Shown are findings in patients with: GNE-related hereditary inclusion body myopathy (A-D), myofibrillar 
myopathy caused by FLNC mutation (E-H), glycogen storage disease type II (I-L), dermatomyositis (M-P), polymyositis 
(Q-T) and a morphological diagnosis of polymyositis but a typical sIBM clinical phenotype (U-X). Serial skeletal muscle 
sections were stained with H&E and double-immunostained with antibodies recognizing FYCO1 (green) and the 
constituent muscle protein spectrin (red). Nuclei were stained with DAPI (blue). RVs in hereditary inclusion body 
myopathy, myofibrillar myopathy and glycogen storage disease type II showed a strong immunoreactivity for FYCO1. 
In myofibrillar myopathy, FYCO1 was also located in cytoplasmic protein aggregates. In dermatomyositis, some 
perifascicular muscle fibers showed an increased immunoreactivity for FYCO1 but “punched-out” areas of myofibrillar 
loss were not rimmed or markedly filled with FYCO1. In polymositis and in sIBM with a morphological phenotype of 
polymyositis, muscle fibers surrounded by inflammatory cells displayed a diffuse/punctate immunoreactivity for 
FYCO1. In addition, some fibers showed FYCO1 accumulations in subsarcolemmal areas similar to that found in RV 
areas in sIBM. These areas were basophilic in H&E staining. Scale bar = 50 µm. 
 
Figure 7: Localization of GFP-FYCO1 and mCherry-LC3 in mouse tibialis anterior muscle. GFP-FYCO1-WT (A-
C), GFP-FYCO1-LIRmut (D-F), GFP-FYCO1-P1302L (G-I) and GFP-FYCO1-T1270A (J-L) were co-expressed with 
mCherry-LC3 and visualized via fluorescence microscopy for FYCO1 (A, D, G, J in green on merged), LC3 (B, E, H, K 
in red on merged) and DAPI for nuclei (C, F, I, L in blue on merged).  Scale bar = 25 µm.  M) Quantitation of the 
Pearsons co-localization coefficient for FYCO1 and LC3 in 40 fibers from three independent experiments. Error bars are 
standard deviation and * denotes p value <0.001. 
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TABLES 
Table 1: Rare missense variants in >2 of 62 sIBM patients compared with ALS patients 
Gene 
name 
sIBM patients with rare 
variant 
ALS patients with rare 
variant Statistical 
Significance 
Number Total Percent Number Total Percent 
AHNAK 7 62 11.3 77 680 11.3 1 
ALDH3A2 2 62 3.2 6 680 0.88 0.14 
ASAH1 2 62 3.2 4 680 0.59 0.08 
C3 2 62 3.2 8 680 1.2 0.2 
COL4A2 2 62 3.2 14 680 2.1 0.64 
DMD 4 62 6.5 29 680 4.3 0.51 
DYSF 4 62 6.5 28 680 4.1 0.51 
FYCO1 7 62 11.3 18 680 2.6 0.003 
GSN 2 62 3.2 10 680 1.5 0.61 
HSPG2 10 62 16.1 56 680 8.2 0.06 
LAMA2 2 62 3.2 24 680 3.5 1 
LAMC1 2 62 3.2 16 680 2.4 0.45 
NRAP 5 62 8.1 17 680 2.5 0.03 
SPTAN1 2 62 3.2 9 680 1.3 0.23 
SPTB 4 62 6.5 33 680 4.9 0.8 
UNC45B 3 62 4.8 9 680 1.3 0.07 
XIRP2 4 62 6.5 48 680 7.1 1 
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Figure 1: Functional classification of proteins identified as overrepresented in RV samples by proteomic 
analysis. Bar chart showing the sum of the mean proportion of proteins assigned to a subgroup is given for 
RV and control samples in per mill of total spectral counts. The number of detected proteins is given in 
brackets behind the subgroup name. Black bars show the proportion in RV samples and grey bars the 
proportion in control samples. Details of proteins assigned to the different subgroups are provided in 
Supplementary Table 1. ER: endoplasmic reticulum.  
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Figure 2: Schematic of FYCO1. Black arrows denote sites of missense variants identified in patients with 
sIBM. Red arrows denote mutations previously identified in patients with congenital cataracts. Domains 
include RUN (GTPase interacting motif); Coiled Coil (dimerization motif); FYVE (phospholipid binding 
region); LIR (LC3 interacting region); and GOLD (golgi dynamics domain).  
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Figure 3: Co-localization of FYCO1, p62 and LC3 in RVs of sIBM patients. Serial skeletal muscle sections 
from two sIBM patients (patient 1: A-H, patient 2: I-P) and from a healthy control (Q-T) were stained with 
H&E and double-immunostained with primary antibodies directed against FYCO1 (green) and p62 or LC3 
(red). Nuclei are stained with DAPI (blue). For each sIBM patient two different RV containing areas of the 
muscle samples are displayed. All RVs show a strong immunoreactivity for FYCO1, p62 and LC3. The co-
localization of FYCO1 with p62 LC3 is indicated by yellow in the merged images. Scale bar = 50 µm.  
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Figure 4: Validation of proteomic findings by immunolocalization studies I. Serial sections from two sIBM 
patients were stained with H&E and double-immunostained with antibodies recognizing desmin, nestin, 
syncoilin, fibrillin-1, nexilin, N-RAP, XIRP-2, leiomodin-2, clusterin, rab35, synaptogyrin, and alphaB-
crystallin. All proteins showed an accumulation in RV samples (red) and FYCO1 (green) as a positive control 
to localize RVs. Nuclei are stained with DAPI (blue). Increased immunoreactivity was observed with all 
proteins as indicated by yellow in the merged image. Scale bar = 50 µm.  
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Figure 5: Validation of proteomic findings by immunolocalization studies II. Serial sections from two sIBM 
patients were stained with H&E and double-immunostained with antibodies recognizing calreticulin, 
GRP78/BiP, AHNAK, dysferlin, δ-sarcoglycan and dystrophin All proteins showed an accumulation in RV 
samples (red) and FYCO1 (green) as a positive control to localize RVs. Nuclei are stained with DAPI (blue). 
Increased immunoreactivity was observed with all proteins as indicated by yellow in the merged image. 
Scale bar = 50 µm.  
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Figure 6: Localization of FYCO1 in hereditary myopathies with rimmed vacuoles and in idiopathic 
inflammatory myopathies. Shown are findings in patients with: GNE-related hereditary inclusion body 
myopathy (A-D), myofibrillar myopathy caused by FLNC mutation (E-H), glycogen storage disease type II 
(I-L), dermatomyositis (M-P), polymyositis (Q-T) and a morphological diagnosis of polymyositis but a typical 
sIBM clinical phenotype (U-X). Serial skeletal muscle sections were stained with H&E and double-
immunostained with antibodies recognizing FYCO1 (green) and the constituent muscle protein spectrin 
(red). Nuclei were stained with DAPI (blue). RVs in hereditary inclusion body myopathy, myofibrillar 
myopathy and glycogen storage disease type II showed a strong immunoreactivity for FYCO1. In myofibrillar 
myopathy, FYCO1 was also located in cytoplasmic protein aggregates. In dermatomyositis, some 
perifascicular muscle fibers showed an increased immunoreactivity for FYCO1 but “punched-out” areas of 
myofibrillar loss were not rimmed or markedly filled with FYCO1. In polymositis and in sIBM with a 
morphological phenotype of polymyositis, muscle fibers surrounded by inflammatory cells displayed a 
diffuse/punctate immunoreactivity for FYCO1. In addition, some fibers showed FYCO1 accumulations in 
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subsarcolemmal areas similar to that found in RV areas in sIBM. These areas were basophilic in H&E 
staining. Scale bar = 50 µm.  
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Figure 7: Localization of GFP-FYCO1 and mCherry-LC3 in mouse tibialis anterior muscle. GFP-FYCO1-WT (A-
C), GFP-FYCO1-LIRmut (D-F), GFP-FYCO1-P1302L (G-I) and GFP-FYCO1-T1270A (J-L) were co-expressed 
with mCherry-LC3 and visualized via fluorescence microscopy for FYCO1 (A, D, G, J in green on merged), 
LC3 (B, E, H, K in red on merged) and DAPI for nuclei (C, F, I, L in blue on merged).  Scale bar = 25 
µm.  M) Quantitation of the Pearsons co-localization coefficient for FYCO1 and LC3 in 40 fibers from three 
independent experiments. Error bars are standard deviation and * denotes p value <0.001.  
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Supplementary Table 1. Proteins identified as over-represented in rimmed vacuoles in sIBM samples (n=18).   
        
mean proportion 
[‰]
b
     
identified in 
n samples   
protein 
formerly 
described 
in sIBM 
mutation 
associated 
with 
myopathy   entry
a
 gene protein RV CONT ratio p value RV CONT   
intermediate filaments (n=5)                 
 
P17661 DES desmin
c
 17.47 6.90 2.53 0.00013 18 14  yes yes (with RVs) 
 P48681 NES nestin
d
 4.07 0.55 7.44 0.00001 17 7   yes  
 
P02545 LMNA prelamin-A/C 3.83 1.11 3.46 0.00002 17 13   Yes 
 P08670 VIM vimentin 2.13 0.62 3.44 0.00236 15 8   yes  
 
Q9H7C4 SYNC syncoilin
e
 0.19 0.00 n.a. 0.00274 9 0    
                       
extracellular matrix/ basal lamina (n=12)          
  P12111 COL6A3 collagen alpha-3(VI) chain 9.22 3.69 2.50 0.00254 18 14   yes Yes 
 
P12109 COL6A1 collagen alpha-1(VI) chain 2.92 0.92 3.19 0.00007 18 11   Yes 
 P35555 FBN1 fibrillin-1
f
 2.01 0.31 6.50 0.00060 14 7   yes  
 
P12110 COL6A2 collagen alpha-2(VI) chain 1.68 0.48 3.48 0.00004 16 12  yes yes 
  
P98160 HSPG2 basement membrane-
specific heparan sulfate 
proteoglycan core protein 
1.55 0.27 5.75 0.00081 15 4   yes  
 
P08572 COL4A2 collagen alpha-2(IV) chain 0.73 0.25 2.88 0.00179 15 10    
 P02452 COL1A1 collagen alpha-1(I) chain 0.57 0.16 3.68 0.04220 13 6     
 
P51884 LUM lumican 0.53 0.16 3.35 0.00203 14 5  yes  
 P07585 DCN decorin 0.45 0.10 4.77 0.00401 13 3     
O75339 CILP cartilage intermediate layer 
protein 1 (CILP-1) 
0.28 0.03 9.03 0.02184 9 1    
  P39059 COL15A1 collagen alpha-1(XV) chain 0.14 0.00 n.a. 0.00304 8 0     
P23946 CMA1 chymase 0.05 0.00 n.a. 0.04308 4 0    
                        
chaperone/stress response/protein degradation (n=29)          
  
P02511 CRYAB alpha-crystallin B chain
g
 
(Alpha(B)-crystallin) 
3.56 2.16 1.64 0.01685 18 13   yes yes (with RVs) 
P11021 HSPA5 78 kDa glucose-regulated 
protein
h
 (GRP-78; BiP) 
1.58 0.62 2.53 0.00025 16 13  Yes  
  
P55072 VCP transitional endoplasmic 
reticulum ATPase (Valosin-
containing protein, VCP) 
1.53 0.75 2.05 0.00424 16 12    yes (with RVs) 
P38646 HSPA9 stress-70 protein, 
mitochondrial 
1.04 0.52 1.99 0.01262 15 12    
  P07355 ANXA2 annexin A2 1.01 0.46 2.21 0.00017 18 12   Yes  
P07339 CTSD cathepsin D 0.84 0.18 4.71 0.00003 16 8  yes  
  
Q9BQS8 FYCO1 FYVE and coiled-coil domain-
containing protein 1
i
 
(FYCO1) 
0.53 0.00 n.a. 0.00245 10 0     
Q13501 SQSTM1 sequestosome-1
j
 0.46 0.00 n.a. 0.00153 14 0  yes yes (with RVs) 
  Q8IWX7 UNC45B protein unc-45 homolog B 0.42 0.14 2.97 0.02098 14 7     
P07602 PSAP prosaposin 0.36 0.13 2.80 0.01031 14 7    
  P14625 HSP90B1 endoplasmin 0.33 0.05 7.00 0.01287 9 2     
P45974 USP5 ubiquitin carboxyl-terminal 
hydrolase 5 
0.30 0.05 6.13 0.00087 13 5    
  P27797 CALR calreticulin (CRP55)
k
 0.24 0.04 6.70 0.00155 12 3   yes  
P32456 GBP2 interferon-induced 
guanylate-binding protein 2 
0.23 0.05 5.12 0.03704 7 2    
  
P50990 CCT8 T-complex protein 1 subunit 
theta (TCP-1-theta) 
0.22 0.07 3.18 0.02774 11 5     
Q12988 HSPB3 heat shock protein beta-3 
(HspB3) 
0.20 0.07 2.72 0.02141 13 5    
  
Q15084 PDIA6 protein disulfide-isomerase 
A6 
0.19 0.01 14.79 0.00124 11 1     
P31948 STIP1 stress-induced-
phosphoprotein 1 (STI1) 
0.19 0.04 5.14 0.00310 11 3    
  
P50991 CCT4 T-complex protein 1 subunit 
delta (TCP-1-delta) 
0.18 0.02 10.75 0.01260 9 1     
P40227 CCT6A T-complex protein 1 subunit 
zeta (TCP-1-zeta) 
0.17 0.04 4.15 0.02131 9 3    
  P37837 TALDO1 transaldolase (EC 2.2.1.2) 0.17 0.00 n.a. 0.00038 10 0     
P25786 PSMA1 proteasome subunit alpha 
type-1 
0.16 0.05 3.48 0.00404 13 5    
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[‰]
b
     
identified in 
n samples   
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mutation 
associated 
with 
myopathy   entry
a
 gene protein RV CONT ratio p value RV CONT   
  
P17987 TCP1  T-complex protein 1 subunit 
alpha (TCP-1-alpha) 
0.13 0.01 12.87 0.01448 7 1     
 
P23284 PPIB peptidyl-prolyl cis-trans 
isomerase B (PPIase B) 
0.13 0.01 12.64 0.02001 7 1    
  
P13473 LAMP2 lysosome-associated 
membrane glycoprotein 2 
(LAMP-2) 
0.12 0.03 3.93 0.00713 11 3    yes (with RVs) 
 
O43760 SYNGR2 synaptogyrin-2
l
 0.08 0.00 n.a. 0.00479 7 0    
  
Q13200 PSMD2 26S proteasome non-ATPase 
regulatory subunit 2 
0.07 0.00 n.a. 0.02500 5 0     
 
P40306 PSMB10 proteasome subunit beta 
type-10 
0.04 0.00 n.a. 0.04225 4 0  yes  
  
O95816 BAG2 BAG family molecular 
chaperone regulator 2 (BAG-
2) 
0.04 0.00 n.a. 0.04294 4 0     
            
sarcolemmal protein (n=12)                 
Q09666 AHNAK neuroblast differentiation-
associated protein AHNAK
m
 
3.43 0.57 5.98 0.00021 16 12  yes  
  O75923 DYSF dysferlin
n
 2.15 0.70 3.07 0.00052 16 12   yes yes 
P55268 LAMB2 laminin subunit beta-2 1.16 0.21 5.51 0.00130 14 7    
  P24043 LAMA2 laminin subunit alpha-2 1.13 0.11 9.93 0.00239 13 4   yes yes 
P11532 DMD dystrophin
o
 0.92 0.11 8.13 0.00151 15 5  yes yes 
  P11047 LAMC1 laminin subunit gamma-1 0.83 0.15 5.46 0.00051 14 5     
Q14BN4 SLMAP sarcolemmal membrane-
associated protein 
0.46 0.19 2.49 0.04775 13 8    
  
Q13813 SPTAN1 spectrin alpha chain, non-
erythrocytic 1
p
 
0.43 0.04 10.60 0.00620 13 1   yes   
P11277 SPTB spectrin beta chain, 
erythrocytic 
0.25 0.01 20.84 0.00624 11 1    
  Q16586 SGCA alpha-sarcoglycan 0.15 0.03 4.80 0.00677 10 3    yes 
Q01082 SPTBN1 spectrin beta chain, non-
erythrocytic 1 
0.15 0.04 4.20 0.03718 8 3    
  Q92629 SGCD delta-sarcoglycan
q
 0.09 0.00 n.a. 0.03592 5 0   yes yes 
            
sarcomere (n=4)                   
Q86VF7 NRAP nebulin-related-anchoring 
protein
r
 (N-RAP) 
2.14 0.39 5.43 0.00315 15 5    
  
A4UGR9 XIRP2 xin actin-binding repeat-
containing protein 2
s
 (XIRP-
2) 
2.10 0.16 12.82 0.00364 13 3     
Q15124 PGM5 phosphoglucomutase-like 
protein 5 (Aciculin) 
0.60 0.30 2.02 0.03617 13 12    
  Q0ZGT2 NEXN nexilin
t
 0.26 0.06 4.27 0.00925 12 5     
            
immune response (n=17)                 
 
P01834 IGKC Ig kappa chain C region 1.37 0.79 1.74 0.00744 17 12  yes  
 P01857 IGHG1 Ig gamma-1 chain C region 1.14 0.54 2.09 0.00197 16 11     
 
P02794 FTH1 ferritin heavy chain 1.05 0.44 2.36 0.00241 16 12    
 P01009 SERPINA1 alpha-1-antitrypsin 0.88 0.38 2.33 0.00122 16 13   yes  
P30101 PDIA3 protein disulfide-isomerase 
A3 
0.72 0.22 3.19 0.01191 13 8    
  P01024 C3 complement C3 0.54 0.11 4.83 0.00311 12 4   yes  
P26038 MSN moesin 0.31 0.01 30.77 0.01863 11 1    
  P01023 A2M alpha-2-macroglobulin 0.30 0.04 7.84 0.01817 10 2     
P10909 CLU clusterin
u
 0.30 0.05 5.62 0.04889 11 3    
  P02675 FGB fibrinogen beta chain 0.25 0.04 5.52 0.03488 9 3   yes  
 
P25789 PSMA4 proteasome subunit alpha 
type-4 
0.23 0.07 3.19 0.01234 13 5    
 P13796 LCP1 plastin-2 0.20 0.01 19.31 0.04443 6 1     
 
P02679 FGG fibrinogen gamma chain 0.16 0.01 15.60 0.04354 6 1    
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 gene protein RV CONT ratio p value RV CONT   
  
Q13151 HNRNPA0 heterogeneous nuclear 
ribonucleoprotein A0 
(hnRNP A0) 
0.16 0.04 4.38 0.01175 11 3     
 
P05556 ITGB1 integrin beta-1 0.07 0.00 n.a. 0.04065 4 0  yes  
 Q15773 MLF2 myeloid leukemia factor 2 0.06 0.00 n.a. 0.02476 5 0     
 
Q15286 RAB35 ras-related protein Rab-35
v
 0.05 0.00 n.a. 0.01971 5 0    
                        
actin dynamics (n=16)          
  P06396 GSN gelsolin 2.12 1.32 1.60 0.03413 18 12   yes yes (with RVs) 
P18206 VCL vinculin 1.29 0.50 2.60 0.00202 16 11    
  
P27816 MAP4 microtubule-associated 
protein 4 (MAP-4) 
0.62 0.16 3.77 0.00023 15 9     
 
Q9UKS6 PACSIN3 protein kinase C and casein 
kinase substrate in neurons 
protein 3 
0.57 0.09 6.05 0.00010 15 6    
 P21333 FLNA filamin-A 0.49 0.05 9.50 0.04333 8 2   yes  
Q5BKX8 MURC muscle-related coiled-coil 
protein 
0.45 0.02 18.72 0.00001 15 3    
  P12829 MYL4 myosin light chain 4 0.34 0.11 3.00 0.02056 12 5     
Q7Z406 MYH14 myosin-14 0.28 0.01 30.89 0.00115 13 1   yes 
  Q6P5Q4 LMOD2 leiomodin-2
w
 0.17 0.05 3.19 0.04642 9 3    yes 
 
P59998 ARPC4 actin-related protein 2/3 
complex subunit 4 
0.16 0.05 3.40 0.04140 9 3    
 P40121 CAPG macrophage-capping protein 0.11 0.00 n.a. 0.00675 7 0     
 
A7E2Y1 MYH7B myosin-7B 0.10 0.00 n.a. 0.04630 5 0  yes yes (with RVs) 
 O75128 COBL protein cordon-bleu 0.10 0.00 n.a. 0.00358 8 0     
Q14847 LASP1 LIM and SH3 domain protein 
1 (LASP-1) 
0.08 0.02 4.48 0.03806 7 2    
  
Q9BPX5 ARPC5L actin-related protein 2/3 
complex subunit 5-like 
protein 
0.07 0.00 n.a. 0.00353 7 0     
 
O15143 ARPC1B actin-related protein 2/3 
complex subunit 1B 
0.04 0.00 n.a. 0.04225 4 0    
                        
nucleus/DNA (n=14)           
  P62805 HIST1H4A histone H4 2.24 0.99 2.27 0.00015 18 13     
P22626 HNRNPA2B1 heterogeneous nuclear 
ribonucleoproteins A2/B1 
1.08 0.06 17.05 0.00002 17 3  yes yes (with RVs) 
  
Q96AQ6 PBXIP1 pre-B-cell leukemia 
transcription factor-
interacting protein 1 
0.70 0.18 3.89 0.00115 13 9     
Q13148 TARDBP TAR DNA-binding protein 43 
(TDP-43) 
0.56 0.01 47.23 0.00010 14 1  yes  
  
P61978 HNRNPK heterogeneous nuclear 
ribonucleoprotein K 
0.50 0.21 2.37 0.01824 15 8     
P19338 NCL Nucleolin 0.35 0.07 4.72 0.00700 11 3    
  O75367 H2AFY core histone macro-H2A.1 0.17 0.02 8.93 0.00009 13 2     
Q14974 KPNB1 importin subunit beta-1 0.15 0.03 4.58 0.00611 11 3    
  
Q00839 HNRNPU heterogeneous nuclear 
ribonucleoprotein U 
0.14 0.00 n.a. 0.00795 7 0     
Q8WWI1 LMO7 LIM domain only protein 7 0.13 0.00 n.a. 0.00972 7 0    
  Q9UN42 ATP1B4 protein ATP1B4 0.10 0.00 n.a. 0.02034 5 0     
Q9UQ80 PA2G4 proliferation-associated 
protein 2G4 
0.08 0.00 n.a. 0.01433 6 0    
  
Q14103 HNRNPD heterogeneous nuclear 
ribonucleoprotein D0 
0.07 0.00 n.a. 0.00363 7 0    yes (with RVs) 
Q9C0J9 BHLHE41 class E basic helix-loop-helix 
protein 41 
0.06 0.00 n.a. 0.02424 5 0    
                        
cytoplasmic vesicle (n=21)          
  P04083 ANXA1 annexin A1 0.75 0.33 2.28 0.01538 15 10   yes  
P50995 ANXA11 annexin A11 0.74 0.23 3.18 0.01089 15 11    
Page 31 of 33
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
Supplementary Table 1. Proteins identified as over-represented in rimmed vacuoles in sIBM samples (n=18).   
        
mean proportion 
[‰]
b
     
identified in 
n samples   
protein 
formerly 
described 
in sIBM 
mutation 
associated 
with 
myopathy   entry
a
 gene protein RV CONT ratio p value RV CONT   
  
Q14204 DYNC1H1 cytoplasmic dynein 1 heavy 
chain 1 
0.64 0.12 5.32 0.00095 13 6     
O60664 PLIN3 perilipin-3 0.50 0.19 2.60 0.03125 14 8    
  
Q16555 DPYSL2 dihydropyrimidinase-related 
protein 2 
0.39 0.04 9.56 0.01625 10 1     
 
Q00610 CLTC clathrin heavy chain 1 0.30 0.01 29.06 0.00064 11 1  yes  
 Q13510 ASAH1 acid ceramidase 0.27 0.00 n.a. 0.00008 12 0     
P15088 CPA3 mast cell carboxypeptidase 
A 
0.23 0.02 11.10 0.00418 9 2    
  
Q9NZN4 EHD2 EH domain-containing 
protein 2 
0.20 0.04 5.54 0.01762 9 3     
 
P02765 AHSG alpha-2-HS-glycoprotein 0.17 0.02 7.56 0.00176 10 3    
  
P51659 HSD17B4 peroxisomal multifunctional 
enzyme type 2 
0.14 0.00 n.a. 0.00683 7 0     
 
Q14108 SCARB2 lysosome membrane protein 
2 
0.13 0.00 n.a. 0.01048 7 0  yes  
  
Q9P0L0 VAPA vesicle-associated 
membrane protein-
associated protein A 
0.11 0.03 3.62 0.04673 8 3     
 
Q8N3L3 TXLNB beta-taxilin 0.11 0.02 6.35 0.04244 6 1    
  
Q9Y2Q3 GSTK1 glutathione S-transferase 
kappa 1 
0.11 0.03 4.08 0.01601 9 3     
O60784 TOM1 target of Myb protein 1 0.09 0.00 n.a. 0.01492 6 0    
  O60493 SNX3 sorting nexin-3 0.08 0.00 n.a. 0.01335 6 0     
O14773 TPP1 tripeptidyl-peptidase 1 0.07 0.00 n.a. 0.00936 6 0    
  
Q17RC7 EXOC3L4 exocyst complex component 
3-like protein 4 
0.04 0.00 n.a. 0.04226 4 0     
O75396 SEC22B vesicle-trafficking protein 
SEC22b 
0.04 0.00 n.a. 0.04758 4 0    
  
Q6IAA8 LAMTOR1 ragulator complex protein 
LAMTOR1 
0.04 0.00 n.a. 0.04247 4 0     
            
ribosome (n=26)                   
P62917 RPL8 60S ribosomal protein L8 0.45 0.01 43.78 0.00137 14 1    
  P08865 RPSA 40S ribosomal protein SA 0.44 0.13 3.50 0.00197 15 8     
P36578 RPL4 60S ribosomal protein L4 0.38 0.10 3.90 0.02199 14 5    
  Q02878 RPL6 60S ribosomal protein L6 0.33 0.13 2.57 0.00770 14 8     
P18124 RPL7 60S ribosomal protein L7 0.32 0.12 2.66 0.01253 13 8    
  P62424 RPL7A 60S ribosomal protein L7a 0.32 0.07 4.29 0.00050 13 6     
Q07020 RPL18 60S ribosomal protein L18 0.31 0.12 2.60 0.01403 13 8    
  P06748 NPM1 Nucleophosmin 0.29 0.03 11.33 0.00029 12 2     
P62750 RPL23A 60S ribosomal protein L23a 0.23 0.07 3.37 0.01208 12 4    
  P62269 RPS18 40S ribosomal protein S18 0.20 0.06 3.52 0.02451 9 5     
P62753 RPS6 40S ribosomal protein S6 0.19 0.05 4.04 0.01609 9 5    
  P62241 RPS8 40S ribosomal protein S8 0.18 0.03 6.15 0.01352 10 2     
P62701 RPS4X 40S ribosomal protein S4, X 
isoform  
0.16 0.04 4.01 0.02938 9 3    
  P30050 RPL12 60S ribosomal protein L12 0.15 0.04 3.65 0.04340 8 4     
P61353 RPL27 60S ribosomal protein L27 0.15 0.05 2.86 0.02457 11 5    
  P62280 RPS11 40S ribosomal protein S11 0.15 0.02 7.08 0.01508 8 2     
P46781 RPS9 40S ribosomal protein S9 0.12 0.02 5.24 0.01028 9 2    
  P61247 RPS3A 40S ribosomal protein S3a 0.12 0.01 19.14 0.02986 6 1     
P62906 RPL10A 60S ribosomal protein L10a 0.12 0.04 2.88 0.03744 10 3    
  P18621 RPL17 60S ribosomal protein L17 0.11 0.01 13.23 0.00960 7 1     
P15880 RPS2 40S ribosomal protein S2 0.11 0.03 3.88 0.03004 8 3    
  Q02543 RPL18A 60S ribosomal protein L18a 0.08 0.01 7.62 0.00959 8 1     
P39019 RPS19 40S ribosomal protein S19 0.07 0.00 n.a. 0.01043 6 0    
  P18077 RPL35A 60S ribosomal protein L35a 0.07 0.01 8.23 0.03619 6 1     
P62888 RPL30 60S ribosomal protein L30 0.06 0.00 n.a. 0.02211 5 0    
  P25398 RPS12 40S ribosomal protein S12 0.04 0.00 n.a. 0.04573 4 0     
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mitochondrium/ER (n=11)                 
P00387 CYB5R3 NADH-cytochrome b5 
reductase 3 
0.76 0.45 1.68 0.03336 16 13    
  P19367 HK1 hexokinase-1 0.49 0.16 3.08 0.04469 13 3     
 
P30837 ALDH1B1 aldehyde dehydrogenase X, 
mitochondrial 
0.31 0.03 11.19 0.01122 8 2    
  
P51648 ALDH3A2 fatty aldehyde 
dehydrogenase 
0.24 0.04 5.87 0.00266 12 3     
 
Q96IX5 USMG5 up-regulated during skeletal 
muscle growth protein 5 
0.22 0.11 1.97 0.01170 14 10    
  
Q99714 HSD17B10 3-hydroxyacyl-CoA 
dehydrogenase type-2 
0.10 0.01 10.11 0.03321 6 1     
Q9Y4W6 AFG3L2 AFG3-like protein 2 0.10 0.02 5.62 0.02579 7 2    
  
Q04837 SSBP1 single-stranded DNA-binding 
protein, mitochondrial 
0.05 0.00 n.a. 0.02226 5 0     
 
O43837 IDH3B isocitrate dehydrogenase 
[NAD] subunit beta, 
mitochondrial 
0.05 0.00 n.a. 0.04991 4 0    
  
Q9NR28 DIABLO diablo homolog, 
mitochondrial 
0.04 0.00 n.a. 0.04086 4 0     
P05141 SLC25A5 ADP/ATP translocase 2 0.04 0.00 n.a. 0.04171 4 0    
                        
cytoskeleton (n=8)           
  Q9NY65 TUBA8 tubulin alpha-8 chain 0.21 0.03 6.25 0.00394 10 4     
P15311 EZR ezrin 0.10 0.00 n.a. 0.01063 7 0    
  
Q01518 CAP1 adenylyl cyclase-associated 
protein 1 (CAP 1) 
0.09 0.00 n.a. 0.02549 5 0     
 
Q13885 TUBB2A tubulin beta-2A chain 0.08 0.01 8.94 0.01472 7 1    
  
Q9BW30 TPPP3 tubulin polymerization-
promoting protein family 
member 3 
0.06 0.00 n.a. 0.02683 5 0     
A6NL28  putative tropomyosin alpha-
3 chain-like protein 
0.06 0.00 n.a. 0.02419 5 0    
  
Q9UPY8 MAPRE3 microtubule-associated 
protein RP/EB family 
member 3 
0.05 0.00 n.a. 0.01949 5 0     
Q13884 SNTB1 beta-1-syntrophin 0.04 0.00 n.a. 0.04284 4 0    
                        
ß-amyloid metabolic process (n=3)          
  
P13798 APEH acylamino-acid-releasing 
enzyme 
0.21 0.07 2.85 0.03190 10 6     
P02743 APCS serum amyloid P-component 
(SAP) 
0.18 0.05 3.93 0.03460 9 3    
  P02766 TTR transthyretin (ATTR) 0.12 0.03 4.59 0.03775 7 2   yes yes 
            
others (n=35)                   
 
P02768 ALB serum albumin 18.01 9.81 1.84 0.00914 18 14  yes  
 P02787 TF serotransferrin 1.58 0.69 2.30 0.01194 16 11     
P12277 CKB creatine kinase B-type 1.30 0.83 1.57 0.02645 17 13  yes  
  
Q6NZI2 PTRF polymerase I and transcript 
release factor 
0.68 0.11 6.14 0.00003 15 4    yes 
P07099 EPHX1 epoxide hydrolase 1 0.30 0.11 2.65 0.01974 12 7    
  
P00488 F13A1 coagulation factor XIII A 
chain 
0.26 0.03 9.05 0.03092 8 2     
P23327 HRC sarcoplasmic reticulum 
histidine-rich calcium-
binding protein 
0.25 0.11 2.21 0.01544 14 7    
  P55290 CDH13 cadherin-13 0.21 0.03 8.18 0.00072 12 2     
Q9BSJ8 ESYT1 extended synaptotagmin-1 0.20 0.05 3.74 0.01819 10 4    
  
P60953 CDC42 cell division control protein 
42 homolog 
0.17 0.06 2.79 0.02086 12 4     
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P52209 PGD 6-phosphogluconate 
dehydrogenase, 
decarboxylating 
0.17 0.02 9.53 0.02768 7 1    
  
Q96MG2 JSRP1 junctional sarcoplasmic 
reticulum protein 1 
0.15 0.05 3.28 0.04894 10 4     
Q8N1G4 LRRC47 leucine-rich repeat-
containing protein 47 
0.15 0.02 8.63 0.00641 9 2    
  P24534 EEF1B2 elongation factor 1-beta 0.15 0.03 5.12 0.00445 11 2     
 
Q9NSD9 FARSB phenylalanine-tRNA ligase 
beta subunit 
0.15 0.02 9.14 0.00146 11 2    
  
Q99735 MGST2 microsomal glutathione S-
transferase 2 
0.15 0.07 2.04 0.04410 13 6     
Q9UBX5 FBLN5 fibulin-5 0.13 0.01 15.49 0.00200 10 1    
  
Q15582 TGFBI transforming growth factor-
beta-induced protein ig-h3 
0.12 0.01 14.42 0.01779 6 1     
 
P27348 YWHAQ 14-3-3 protein theta 0.11 0.03 3.99 0.02571 9 2    
  
Q15056 EIF4H eukaryotic translation 
initiation factor 4H 
0.10 0.03 3.59 0.02310 9 3     
P02792 FTL ferritin light chain 0.10 0.00 n.a. 0.00567 7 0    
  
Q9C0A0 CNTNAP4 contactin-associated 
protein-like 4 
0.10 0.00 n.a. 0.00234 8 0     
 
P16671 CD36 platelet glycoprotein 4 0.09 0.01 8.06 0.03107 6 1  yes  
  
Q96KP4 CNDP2 cytosolic non-specific 
dipeptidase 
0.09 0.00 n.a. 0.01315 6 0     
P19878 NCF2 neutrophil cytosol factor 2 0.09 0.02 4.37 0.03966 7 2    
  P31949 S100A11 protein S100-A11 0.09 0.02 4.54 0.04703 7 2     
 
Q9Y394 DHRS7 dehydrogenase/reductase 
SDR family member 7 
0.08 0.00 n.a. 0.00727 7 0  yes  
 P37802 TAGLN2 transgelin-2 0.07 0.00 n.a. 0.02730 5 0     
Q96CX2 KCTD12 BTB/POZ domain-containing 
protein KCTD12 
0.07 0.00 n.a. 0.02838 5 0    
  O95336 PGLS 6-phosphogluconolactonase 0.06 0.00 n.a. 0.00871 6 0     
Q99584 S100A13 protein S100-A13 0.06 0.00 n.a. 0.04515 4 0    
  
P51857 AKR1D1 3-oxo-5-beta-steroid 4-
dehydrogenase 
0.05 0.00 n.a. 0.02937 5 0     
P05198 EIF2S1 eukaryotic translation 
initiation factor 2 subunit 1 
0.05 0.00 n.a. 0.01921 5 0    
  O00168 FXYD1 phospholemman 0.04 0.00 n.a. 0.04161 4 0     
  
P48163 ME1 NADP-dependent malic 
enzyme 
0.04 0.00 n.a. 0.04297 4 0     
RV: rimmed vacuoles samples; CONT: control samples; 
a
UniProt accession number; n.a.: not applicable; 
b
per mill of total spectral counts;  
c-w
results validated by immunofluorescence studies using the following primary antibodies: c: mouse monoclonal antibody (mmAb) clone D33, 
DAKO, diluation 1/500; d: rabbit polyclonal antibody (rpAb) HPA007007, Sigma-Aldrich, 1/500; e: rpAb HPA028311, Sigma-Aldrich, 1/200; f: rpAb 
ab53076, Abcam, 1/50; g: mmAb clone G2JF, Novocastra/Leica, 1/100; h: rpAb ab21685, Abcam, 1/1000; i: rpAb HPA035526, Sigma, 1/200; 
mmAb ab56416, Abcam, 1/1000; k: rpAb ab2907, Abcam, 1/200; l: rpAb PAB19176, Abnova, 1/250; m: rpAb HPA026643, Sigma, 1/500; n: mmAb 
clone HAM1/7B4, Novocastra/Leica, 1/30; o: mmAb clone D4/6D3, Novocastra/Leica, 1/20; p: mmAb clone RBC2/3D5, Novocastra/Leica, 1/150; 
q: mmAb clone δSARC/12C1, Novocastra/Leica, 1/100; r: rpAb custom made, BioGenes, 1/500; s: rpAb clone Xirp2 (custom made, PFM van der 
Ven et al. Exp Cell Res 2006), 1/500; t: rpAb HPA011185, Sigma, 1/2000; u: mmAb Hs-3, BioVendor, 1/25; v: rpAb ab105762, Abcam, 1/500; w: 
rpAb clone LMOD2, Abgent, 1/100. 
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Supplementary Table 2: FYCO1 Rare Missense Coding Variants in sIBM patients 
Age at 
Collection 
Sex Race Ref Alt Genotype 
Predicted  
cDNA Change 
Predicted Protein 
Change 
ExAC Allele 
Frequency 
SIFT 
Prediction 
PolyPhen2 
Prediction 
Mutation 
Taster 
dbSNP 
ID 
77 F Cauc A G A/G c.452T>C p.Val151Ala 0.00015 damaging 
probably-
damaging 
disease 
causing 
rs14208
1868 
66 F Cauc T C T/C c.1157A>G p.Lys386Arg 0 tolerated 
possibly-
damaging 
polymorphism none 
57 M Cauc C G C/G c.1971G>C p.Gln657His 0.000008 damaging 
possibly-
damaging 
polymorphism none 
56 M Cauc G C G/C c.2514C>G p.Asn838Lys 0.00003 damaging 
probably-
damaging 
disease 
causing 
rs14168
9540 
55 M Cauc G T G/T c.3234C>A p.Asp1078Glu 0.001 tolerated benign polymorphism 
rs67955
30 
59 F Cauc T C T/C c.3808A>G p.Thr1270Ala 0.00007 tolerated benign polymorphism 
rs14524
4537 
76 M Cauc G A G/A c.3905C>T p.Pro1302Leu 0.00001 damaging 
probably-
damaging 
disease 
causing 
none 
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